Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 23, 2021
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
[ Tue, Feb 23rd 2021
] - WOPRAI
Bill Sutherland Maintained (AMED) at Strong Buy with Increased Target to $325 on, Feb 23rd, 2021
Bill Sutherland of Benchmark, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Increased Target from $275 to $325 on, Feb 23rd, 2021.
Bill has made no other calls on AMED in the last 4 months.
There are 2 other peers that have a rating on AMED. Out of the 2 peers that are also analyzing AMED, 0 agree with Bill's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Bill
- Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $340 on, Monday, February 8th, 2021
- A.J. Rice of "Credit Suisse" Maintained at Buy with Increased Target to $280 on, Friday, October 30th, 2020
